Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Input: Consider Input: Context: Benzodiazepine (BZD) overdose (OD) continues to cause significant morbidity and mortality in the UK. Flumazenil is an effective antidote but there is a risk of seizures, particularly in those who have co-ingested tricyclic antidepressants. A study was undertaken to examine the frequency of use, safety and efficacy of flumazenil in the management of BZD OD in the UK. A 2-year retrospective cohort study was performed of all enquiries to the UK National Poisons Information Service involving BZD OD. Flumazenil was administered to 80 patients in 4504 BZD-related enquiries, 68 of whom did not have ventilatory failure or had recognised contraindications to flumazenil. Factors associated with flumazenil use were increased age, severe poisoning and ventilatory failure. Co-ingestion of tricyclic antidepressants and chronic obstructive pulmonary disease did not influence flumazenil administration. Seizure frequency in patients not treated with flumazenil was 0.3%. The frequency of prior seizure in flumazenil-treated patients was 30 times higher (8.8%). Seven patients who had seizures prior to flumazenil therapy had no recurrence of their seizures. Ventilation or consciousness improved in 70% of flumazenil-treated patients. Flumazenil administration was followed by one instance each of agitation and brief seizure. Flumazenil is used infrequently in the management of BZD OD in the UK. It was effective and associated with a low incidence of seizure. These results compare favourably with the results of published randomised controlled trials and cohort studies, although previous studies have not reported the use of flumazenil in such a high-risk population. This study should inform the continuing review of national guidance on flumazenil therapy. 
 Question: Which drug should be used as an antidote in benzodiazepine overdose?

Output: flumazenil


Input: Consider Input: Context: You're in your office when you learn there's someone with a gun wandering outside. You can hear gunshots and screams. What do you do? That's the challenge for users of a new virtual reality program called SurviVR, designed to train employees how to deal with an active shooter situation in the workplace. The program works with HTC Vive, the virtual reality headset released earlier this year. An active shooter situation is when an armed person or people actively shoot in a small, populated area with the intention to kill. There were 20 such situations in the United States last year and 20 the year before, according to FBI statistics, resulting in a total of 231 deaths. This year saw the deadliest active shooter situation in US history , with 49 people killed in a nightclub in Orlando. In the training situation, users have four choices. They can lock themselves in the office. They can hide, perhaps in the office closet. They can run for an exit. Or they can use something in the office--a computer or a cup a pair of scissors-as a weapon to fight the shooter. This is an improvement on standard active shooter training. Gallo says, which typically teachers people to lock themselves in place and hide. The "lock down" method is often ineffective, he says, and has resulted in many deaths in recent years. In the training's basic level, no one gets killed. But as the trainings become more advanced, players who make a wrong choice be shot. There's no blood; the screen simply turns black slowly. If this sounds terrifying, that's the point, says Gallo. There are plenty of training programs to teach employees how to deal with workplace violence, sometimes involving role play with toy guns. But these trainings are basically games. Gallo says, with employees relaxed and even enjoying themselves. To teach people what they really need to know for an active shooter situation, they need to be scared. "SurviVR will take the fear and turn it into confidence." Gallo says. 
 Question: What does Gallo think of the training programs involving role play with toy guns?

Output: ineffective


Input: Consider Input: Context: Increased expression of nerve growth factor in injured or inflamed tissue is associated with increased pain. This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor. We randomly assigned 450 patients with osteoarthritis of the knee to receive tanezumab (administered at a dose of 10, 25, 50, 100, or 200 g per kilogram of body weight) or placebo on days 1 and 56. The primary efficacy measures were knee pain while walking and the patient's global assessment of response to therapy. We also assessed pain, stiffness, and physical function using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); the rate of response using the criteria of the Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative (OMERACT-OARSI); and safety. When averaged over weeks 1 through 16, the mean reductions from baseline in knee pain while walking ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P<0.001). Tanezumab, as compared with placebo, was also associated with significantly greater improvements in the response to therapy as assessed with the use of the patients' global assessment measure (mean increases in score of 29 to 47% with various doses of tanezumab, as compared with 19% with placebo; P0.001). The rate of response according to the OMERACT-OARSI criteria ranged from 74 to 93% with tanezumab treatment, as compared with 44% with placebo (P<0.001). The rates of adverse events were 68% and 55% in the tanezumab and placebo groups, respectively. The most common adverse events among tanezumab-treated patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia (7%). In this proof-of-concept study, treatment with tanezumab was associated with a reduction in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee. (Funded by Rinat Neuroscience; ClinicalTrials.gov number, NCT00394563.). 
 Question: What is the target of tanezumab?


Output: ngf